Mara Goldstein
Stock Analyst at Mizuho
(2.55)
# 2,204
Out of 5,109 analysts
69
Total ratings
48.08%
Success rate
14.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mara Goldstein
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Maintains: Outperform | $32 → $30 | $10.79 | +178.04% | 3 | May 19, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $30 → $10 | $2.82 | +254.61% | 5 | May 12, 2025 | |
| VSTM Verastem | Maintains: Outperform | $9 → $8 | $7.93 | +0.88% | 7 | Apr 9, 2025 | |
| RCUS Arcus Biosciences | Maintains: Buy | $51 → $42 | $22.71 | +84.94% | 4 | Jan 30, 2024 | |
| XNCR Xencor | Maintains: Buy | $59 → $50 | $15.47 | +223.21% | 2 | Jan 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Initiates: Buy | $45 | $21.70 | +107.37% | 1 | Dec 22, 2023 | |
| INCY Incyte | Maintains: Neutral | $82 → $77 | $100.91 | -23.69% | 5 | Dec 14, 2023 | |
| ERAS Erasca | Maintains: Buy | $8 → $7 | $3.39 | +106.49% | 3 | Nov 29, 2023 | |
| FATE Fate Therapeutics | Maintains: Buy | $12 → $8 | $0.98 | +719.00% | 5 | Nov 20, 2023 | |
| NKTR Nektar Therapeutics | Reiterates: Neutral | $90 | $44.46 | +102.43% | 3 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3.5 | $7.37 | -52.51% | 5 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.75 | +20,471.43% | 2 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 → $20 | $6.39 | +212.99% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $130 | $105.04 | +23.76% | 2 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $2 | $4.20 | -52.38% | 6 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $12 | $1.64 | +631.71% | 3 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 → $20 | $63.29 | -68.40% | 3 | Sep 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $34 → $48 | $9.98 | +380.96% | 5 | Jul 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.58 | - | 2 | Apr 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $5.80 | +141.38% | 1 | Oct 12, 2017 |
Kura Oncology
May 19, 2025
Maintains: Outperform
Price Target: $32 → $30
Current: $10.79
Upside: +178.04%
Iovance Biotherapeutics
May 12, 2025
Maintains: Outperform
Price Target: $30 → $10
Current: $2.82
Upside: +254.61%
Verastem
Apr 9, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $7.93
Upside: +0.88%
Arcus Biosciences
Jan 30, 2024
Maintains: Buy
Price Target: $51 → $42
Current: $22.71
Upside: +84.94%
Xencor
Jan 22, 2024
Maintains: Buy
Price Target: $59 → $50
Current: $15.47
Upside: +223.21%
Syndax Pharmaceuticals
Dec 22, 2023
Initiates: Buy
Price Target: $45
Current: $21.70
Upside: +107.37%
Incyte
Dec 14, 2023
Maintains: Neutral
Price Target: $82 → $77
Current: $100.91
Upside: -23.69%
Erasca
Nov 29, 2023
Maintains: Buy
Price Target: $8 → $7
Current: $3.39
Upside: +106.49%
Fate Therapeutics
Nov 20, 2023
Maintains: Buy
Price Target: $12 → $8
Current: $0.98
Upside: +719.00%
Nektar Therapeutics
Aug 7, 2023
Reiterates: Neutral
Price Target: $90
Current: $44.46
Upside: +102.43%
Jun 16, 2023
Reiterates: Neutral
Price Target: $3.5
Current: $7.37
Upside: -52.51%
Apr 24, 2023
Reiterates: Buy
Price Target: $360
Current: $1.75
Upside: +20,471.43%
Apr 19, 2023
Upgrades: Buy
Price Target: $10 → $20
Current: $6.39
Upside: +212.99%
Apr 10, 2023
Reiterates: Buy
Price Target: $130
Current: $105.04
Upside: +23.76%
Mar 28, 2023
Maintains: Neutral
Price Target: $4 → $2
Current: $4.20
Upside: -52.38%
Mar 8, 2023
Maintains: Buy
Price Target: $18 → $12
Current: $1.64
Upside: +631.71%
Sep 6, 2019
Reiterates: Overweight
Price Target: $14 → $20
Current: $63.29
Upside: -68.40%
Jul 8, 2019
Downgrades: Neutral
Price Target: $34 → $48
Current: $9.98
Upside: +380.96%
Apr 17, 2018
Downgrades: Neutral
Price Target: n/a
Current: $26.58
Upside: -
Oct 12, 2017
Maintains: Overweight
Price Target: $12 → $14
Current: $5.80
Upside: +141.38%